Items in cart [0] Questions? Call 888-624-8373

PAPERBACK list:$34.00 Web:$30.60 add to cart PDF BOOK your price: $26.50 add to cart Rights & Permissions Free Resources PDF EXECUTIVE SUMMARY Display this book on your site! Related Titles The Infectious Etiology of Chronic Diseases: Defining the Relationship, Enhancing the Research, and Mitigating the Effects -- Workshop Summary The Ethical Conduct of Clinical Research Involving Children Other Related Titles Review of the Fialuridine (FIAU) Clinical Trials (1995) Institute of Medicine (IOM) Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web. Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book. Reference Finder Paste in your own text to find books that relate to your topic. Page 244   E-mail  Facebook  Digg  Stumble  Twitter More The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. E Example of Oclassen Fax Data Summaries Page 244 Front Matter (R1-R10) Executive Summary (1-15) Introduction (16-19) Clinical Trials (20-33) Hepatitis B and Other Viral Diseases (34-41) Clinical Trials of FIAC at Memorial Sloan-Kettering Cancer Center (42-50) Oclassen Clinical Trial R89-001-01 (51-54) Oclassen Clinical Trial R90-001-01 (NIH Protocol 91-AI-0031) (55-60) Oclassen Clinical Trial R91-001-10 (NIH Protocol 91-DK-AI-213) (61-65) Eli Lilly Trial H3X-MC-PPPA (66-69) Eli Lilly Trial H3X-MC-PPPG (70-72) Eli Lilly Trial H3X-MC-PPPC (NIH Protocol 93-DK-0031) (73-89) Summary of Patient Interviews (90-92) Overall Assessment of the Trials (93-97) Recent Studies of FIAU Toxicity (98-103) Review of the FDA Task Force Report 'Fialuridine: Hepatic and Pancreatic Toxicity' (104-120) Review of 'Report to the Advisory Committee to the Director, National Institutes of Health' (121-132) FDA-Proposed Changes to the Code of Federal Regulations (133-142) Ancillary Issues Raised During the Period Following The H3X-MC-PPPC Trial (143-149) Conclusions and Recommendations (150-154) Appendix A: Chronology of FIAU/FIAC Clinical Trials (155-164) Appendix B: Bibliography and References (165-177) Appendix C: Agendas from the Three Committee Meetings (178-183) Appendix D: Informed Consent Documents (184-243) Appendix E: Example of Oclassen Fax Data Summaries (244-245) Appendix F: FIAC and FIAU Preclinical Toxicity Studies (246-250) Appendix G: Patient Summaries, Lilly Trial H3X-MC-PPPA (251-255) Appendix H: Statistical Analysis of Mortality in the FIAU/FIAC Clinical Trials (256-265) Glossary (266-269)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 244
Review of the Fialuridine (FIAU) Clinical Trials E Example of Oclassen Fax Data Summaries

OCR for page 245
Review of the Fialuridine (FIAU) Clinical Trials

Representative terms from entire chapter:

fax data